A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
about
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyUpdates of mTOR inhibitorsmTOR inhibitors in advanced renal cell carcinomaClinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaDifferentiating mTOR inhibitors in renal cell carcinomamTOR kinase inhibitors as potential cancer therapeutic drugsEverolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyDetection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPETEverolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenibPharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.Evaluation of everolimus in renal cell cancer.Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.Enhancing mTOR-targeted cancer therapy.Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further ProposalsTreatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyDynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.Everolimus - a new approach in the treatment of renal cell carcinomaSafety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.Identification of two novel inhibitors of mTOR signaling pathway based on high content screening.Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC).Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale.Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.Current status of targeted therapy for advanced renal cell carcinomaPhase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignanciesNational trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011.Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.Metabolic complications with the use of mTOR inhibitors for cancer therapyThe ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.Cancer in the transplant recipient.Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinomaImpact of genetic alterations on mTOR-targeted cancer therapyMorphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogNoninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro.New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
P2860
Q21198871-1E375D58-1217-47E8-970D-DD99AEF4E585Q24607170-50D0D2B3-CAEE-4504-BE94-476FE480072DQ24612127-E349D487-EB59-4F76-AFC6-C0644A214605Q26783514-6BF8DFA1-D72F-46FE-9BAD-6D1398597E6EQ26860172-E85A0C80-3947-4C92-BE82-9DFEFCF256CCQ27027963-EA0F21AE-963F-492C-820A-349C749DC2CFQ28079861-938875CB-0D34-4B3F-9B3C-A75B2C977B5BQ28487987-37A3A0C1-9967-43EA-885A-D16D6BC1B568Q28765488-D67823AF-6313-4A48-AA19-B4CB981ED0A3Q33397545-61F1BB4B-7A4D-462F-A053-9188497ED472Q33407015-A91CDB1C-B8B7-4EB1-AD8F-DB3347514608Q33410761-2D90B20B-6FE4-4B26-A1E1-EE81D3A16533Q33604979-A49C285D-73D7-445A-93D2-EBBE3556D872Q33698105-71EAF8CB-6763-46C8-A6AE-9F701C3165C7Q33760578-F4586A8F-0250-46D1-9868-25CD901BC826Q33985467-B3731DDB-C616-49F7-A86C-5D5293EE2F3DQ34074997-D449E5E0-55E4-4D79-B973-D8EE7C1DEE51Q34348318-DF2196ED-5A6E-4672-9639-F2708760F8C8Q34417931-24C70BDB-A03A-4823-8ED6-595C1FE20320Q34628575-E8C024FA-44F9-49B0-AE01-DE56D0D94A74Q34915708-FBC701EF-C098-422B-88CD-4A9213308496Q35026441-351A7393-9953-4782-9FA1-77C98B5E87E3Q35157985-03B9C699-7DA4-4DE0-8C38-1A07B7E35B37Q35560862-712FDDBC-A05D-4D4B-92D6-2AEE70D2587EQ35583953-469E7EF8-67CF-4279-9D89-F42EC2330E5BQ35602130-F9AAAC89-048B-4303-9ED1-076117AE9873Q35638434-0CBC9CC5-F482-4FA9-857E-B9B898A5A85EQ35903850-82E2F8C2-D2E3-4D53-A801-A182D55D9110Q36072040-C0A572C4-4A4C-4657-95BC-6891C9F69F85Q36125906-7416E262-7075-40A0-A826-3BB7052627CCQ36553511-52C7FB21-0FD7-42D5-8193-35ED53F913F7Q36553517-5A33DC00-FC9B-4B5A-B10C-6FF6BDEECAB5Q36729436-45A04B3B-D9FB-4362-9F7B-98F230DBB880Q36938488-22892F21-C9EF-4F38-99DF-4B8F616EF8AFQ37283720-AC7F0AAB-5D1F-456E-81E1-0D58C33269E9Q37353954-C71F020F-8214-4666-A0C0-5DCA7E794139Q37520310-97ECD7CC-9908-4806-97C9-1155973688CCQ37701147-5F9FF5B7-2E38-4B6D-B0ED-6E48733A69CBQ37714078-1199A72D-CC92-46BC-BD26-EFCA279CADC9Q37766888-478496BE-13E4-4BAD-8A54-AF4FDD171909
P2860
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase 2 study with a daily r ...... clear cell renal cell cancer.
@ast
A phase 2 study with a daily r ...... clear cell renal cell cancer.
@en
type
label
A phase 2 study with a daily r ...... clear cell renal cell cancer.
@ast
A phase 2 study with a daily r ...... clear cell renal cell cancer.
@en
prefLabel
A phase 2 study with a daily r ...... clear cell renal cell cancer.
@ast
A phase 2 study with a daily r ...... clear cell renal cell cancer.
@en
P2093
P356
P1433
P1476
A phase 2 study with a daily r ...... clear cell renal cell cancer.
@en
P2093
James P Willis
Jaroslaw Jac
Robert J Amato
Sarah Giessinger
Somyata Saxena
P2860
P304
P356
10.1002/CNCR.24280
P407
P577
2009-06-01T00:00:00Z